Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Delgocitinib - LEO Pharma

Next Previous
Drug Profile

Delgocitinib - LEO Pharma

Alternative Names: Anzupgo; CORECTIM; JTE-052; JTE-052A; LEO 124249; LEO 124249 cream; LP-0133

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Japan Tobacco
  • Developer Japan Tobacco; LEO Pharma
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Azetidines; Nitriles; Pyrimidines; Pyrrolidines; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atopic dermatitis; Eczema
  • Phase III Lichen sclerosus et atrophicus
  • Phase II Alopecia areata; Autoimmune disorders; Discoid lupus erythematosus; Hypersensitivity; Inverse psoriasis; Palmoplantar pustulosis
  • No development reported Unspecified

Most Recent Events

  • 21 Jan 2026 Phase-III clinical trials in Lichen sclerosus et atrophicus (Topical) (NCT07335588)
  • 13 Jan 2026 LEO Pharma plans a phase III trial for Lichen-sclerosus-et-atrophicus in May 2026 (Topical) (NCT07335588)
  • 19 Dec 2025 Preregistration for Eczema (In adolescents) in Iceland, Liechtenstein, Norway, European Union (Topical)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top